Artios Pharma: Funding, Investors & Team (Sep 2026)
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
Artios Pharma has raised $267M across 2 funding rounds on record, the most recent a Series D of $115M announced in Nov 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Artios Pharma Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Artios Pharma Funding Rounds
Artios Pharma raised $152M in a Series C announced in Jul 2021.
4.3 years later, a Series D of $115M was announced in Nov 2025.
Artios Pharma Founders and Leadership Team
Contact details for the Artios Pharma team: 3 of 3 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Artios Pharma Funding Compared to Other Biotechnology Startups
Artios Pharma's latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Artios Pharma in Biotechnology and Cambridge
Companies Similar to Artios Pharma
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Artios Pharma Funding FAQs
What does Artios Pharma do?
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
How much funding has Artios Pharma raised?
Artios Pharma has raised $267M across 2 rounds on record. The most recent is a Series D of $115M announced in Nov 2025.
When did Artios Pharma last raise funding?
Artios Pharma's most recent funding round on record is a Series D of $115M, announced in Nov 2025.
Who founded Artios Pharma?
FundedIQ lists Andrew Muncey (Founder) at Artios Pharma.
Who is the CEO of Artios Pharma?
Niall Martin is listed as CEO at Artios Pharma.
Where is Artios Pharma headquartered?
Artios Pharma is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does Artios Pharma have?
Artios Pharma is in the 51-100 employee band.
How does Artios Pharma's funding compare to other Biotechnology startups?
Artios Pharma's latest round of $115M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Artios Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Artios Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.